Aquestive Therapeutics (AQST) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

AQST Stock Forecast

Aquestive Therapeutics stock forecast is as follows: an average price target of $10.25 (represents a 120.91% upside from AQST’s last price of $4.64) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.

AQST Price Target

The average price target for Aquestive Therapeutics (AQST) is $10.25 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $12.00 to $9.00. This represents a potential 120.91% upside from AQST's last price of $4.64.

AQST Analyst Ratings

Buy

According to 5 Wall Street analysts, Aquestive Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for AQST stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Aquestive Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Nov 06, 2024	Thomas Flaten	Loop Capital Markets	$10.00	$4.79	108.82%	115.52%
Jun 25, 2024	Thomas Flaten	Loop Capital Markets	$7.00	$2.31	203.03%	50.86%
Apr 11, 2024	David Amsellem	Piper Sandler	$10.00	$4.07	145.70%	115.52%
Mar 18, 2024	Raghuram Selvaraju	H.C. Wainwright	$9.00	$5.51	63.34%	93.97%
Mar 15, 2024	Francois Brisebois	Oppenheimer	$12.00	$6.09	97.04%	158.62%

Row per page

Go to

The latest Aquestive Therapeutics stock forecast, released on Nov 06, 2024 by Thomas Flaten from Loop Capital Markets, set a price target of $10.00, which represents a 108.82% increase from the stock price at the time of the forecast ($4.79), and a 115.52% increase from AQST last price ($4.64).

Aquestive Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	1	1	5
Avg Price Target	$10.00	$10.00	$9.60
Last Closing Price	$4.64	$4.64	$4.64
Upside/Downside	115.52%	115.52%	106.90%

In the current month, the average price target of Aquestive Therapeutics stock is $10.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 115.52% increase as opposed to Aquestive Therapeutics's last price of $4.64. This month's average price target is down 0.00% compared to last quarter, and up 4.17% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Sep 30, 2024	H.C. Wainwright	Buy	Buy	Hold
Aug 09, 2024	Oppenheimer	Outperform	Outperform	Hold
Jun 25, 2024	Lake Street	Buy	Buy	Hold
May 09, 2024	Alliance Global Partners	Buy	Buy	Hold
Mar 09, 2023	Wedbush	-	Outperform	Upgrade

Row per page

Go to

Aquestive Therapeutics's last stock rating was published by H.C. Wainwright on Sep 30, 2024. The company gave AQST a "Buy" rating, the same as its previous rate.

Aquestive Therapeutics Financial Forecast

Aquestive Therapeutics Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Sep 18
Revenue	-	-	-	-	-	-	-	-	-	$13.00M	$13.24M	$11.13M	$10.68M	$11.46M	$13.27M	$12.27M	$11.08M	$13.29M	$15.35M	$11.12M	$7.15M	$8.26M	$21.68M	$8.77M	$16.42M	$12.42M	$11.13M	$12.64M	$13.27M
Avg Forecast	$15.22M	$13.66M	$13.06M	$13.08M	$13.09M	$12.69M	$12.39M	$12.26M	$11.66M	$11.51M	$11.01M	$9.94M	$10.42M	$11.00M	$10.57M	$10.13M	$9.36M	$11.01M	$9.48M	$8.97M	$6.26M	$8.72M	$8.77M	$10.07M	$15.84M	$9.97M	$9.19M	$11.59M	$8.91M
High Forecast	$17.13M	$15.38M	$14.70M	$14.08M	$15.12M	$12.72M	$12.42M	$13.80M	$12.36M	$11.51M	$12.40M	$11.19M	$11.73M	$11.00M	$10.57M	$10.13M	$9.36M	$11.01M	$9.48M	$8.97M	$6.26M	$8.72M	$8.77M	$10.07M	$15.84M	$9.97M	$9.19M	$11.59M	$10.70M
Low Forecast	$13.99M	$12.55M	$12.00M	$12.28M	$12.12M	$12.65M	$12.36M	$11.27M	$10.88M	$11.51M	$10.12M	$9.13M	$9.57M	$11.00M	$10.57M	$10.13M	$9.36M	$11.01M	$9.48M	$8.97M	$6.26M	$8.72M	$8.77M	$10.07M	$15.84M	$9.97M	$9.19M	$11.59M	$7.13M
# Analysts	1	1	1	4	6	3	2	2	4	2	2	2	1	1	1	1	2	2	2	4	4	6	4	4	7	4	3	7	9
Surprise %	-	-	-	-	-	-	-	-	-	1.13%	1.20%	1.12%	1.03%	1.04%	1.25%	1.21%	1.18%	1.21%	1.62%	1.24%	1.14%	0.95%	2.47%	0.87%	1.04%	1.25%	1.21%	1.09%	1.49%

Aquestive Therapeutics's average Quarter revenue forecast for Dec 23 based on 4 analysts is $11.66M, with a low forecast of $10.88M, and a high forecast of $12.36M. AQST's average Quarter revenue forecast represents a -10.32% decrease compared to the company's last Quarter revenue of $13.00M (Sep 23).

Aquestive Therapeutics EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Sep 18
# Analysts	1	1	1	4	6	3	2	2	4	2	2	2	1	1	1	1	2	2	2	4	4	6	4	4	7	4	3	7	9
EBITDA	-	-	-	-	-	-	-	-	-	$-2.38M	$-4.21M	$9.91M	$-10.65M	$-8.25M	$-12.06M	$-9.01M	$-30.69M	$-7.23M	$-5.40M	$-7.77M	$-14.54M	$-13.12M	$1.21M	$-12.87M	$-9.11M	$-15.05M	$-17.81M	$-12.05M	$-12.36M
Avg Forecast	$-10.80M	$-9.69M	$-9.27M	$-9.28M	$-9.29M	$-9.00M	$-8.79M	$-8.70M	$-8.27M	$-8.17M	$-7.82M	$-7.05M	$-7.39M	$-8.24M	$-7.92M	$-10.99M	$-7.01M	$-8.24M	$-7.09M	$-8.13M	$-4.69M	$-6.53M	$-6.56M	$-12.32M	$-11.86M	$-7.47M	$-6.88M	$-9.88M	$-6.96M
High Forecast	$-9.93M	$-8.91M	$-8.52M	$-8.72M	$-8.60M	$-8.98M	$-8.77M	$-8.00M	$-7.72M	$-8.17M	$-7.18M	$-6.48M	$-6.79M	$-8.24M	$-7.92M	$-8.79M	$-7.01M	$-8.24M	$-7.09M	$-6.51M	$-4.69M	$-6.53M	$-6.56M	$-9.86M	$-11.86M	$-7.47M	$-6.88M	$-7.91M	$-5.56M
Low Forecast	$-12.16M	$-10.91M	$-10.43M	$-9.99M	$-10.73M	$-9.03M	$-8.81M	$-9.79M	$-8.77M	$-8.17M	$-8.80M	$-7.94M	$-8.32M	$-8.24M	$-7.92M	$-13.19M	$-7.01M	$-8.24M	$-7.09M	$-9.76M	$-4.69M	$-6.53M	$-6.56M	$-14.79M	$-11.86M	$-7.47M	$-6.88M	$-11.86M	$-8.35M
Surprise %	-	-	-	-	-	-	-	-	-	0.29%	0.54%	-1.40%	1.44%	1.00%	1.52%	0.82%	4.38%	0.88%	0.76%	0.96%	3.10%	2.01%	-0.18%	1.04%	0.77%	2.02%	2.59%	1.22%	1.78%

2 analysts predict AQST's average Quarter EBITDA for Jun 23 to be $-7.82M, with a high of $-7.18M and a low of $-8.80M. This is -178.88% lower than Aquestive Therapeutics's previous annual EBITDA (Mar 23) of $9.91M.

Aquestive Therapeutics Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Sep 18
# Analysts	1	1	1	4	6	3	2	2	4	2	2	2	1	1	1	1	2	2	2	4	4	6	4	4	7	4	3	7	9
Net Income	-	-	-	-	-	-	-	-	-	$-2.04M	$-5.79M	$19.31M	$-18.15M	$-16.22M	$-19.84M	$-16.70M	$-47.97M	$-14.55M	$-12.37M	$-14.67M	$-20.37M	$-16.55M	$-2.33M	$-16.53M	$-12.64M	$-18.41M	$-20.47M	$-14.73M	$-15.04M
Avg Forecast	$-11.84M	$-11.84M	$-12.20M	$-12.02M	$-12.18M	$-10.70M	$-10.47M	$-8.08M	$-7.74M	$-10.32M	$-10.63M	$-12.75M	$-20.56M	$-26.23M	$-32.55M	$-16.12M	$-42.36M	$-39.82M	$-39.70M	$-15.35M	$-45.82M	$-41.52M	$-40.30M	$-15.83M	$-35.00M	$-65.00M	$-57.58M	$-12.08M	$-8.46M
High Forecast	$-10.59M	$-10.59M	$-10.92M	$-10.31M	$-11.31M	$-9.58M	$-9.37M	$-7.23M	$-3.87M	$-9.24M	$-9.51M	$-11.41M	$-18.40M	$-26.23M	$-32.55M	$-12.90M	$-42.36M	$-39.82M	$-39.70M	$-12.28M	$-45.82M	$-41.52M	$-40.30M	$-12.66M	$-35.00M	$-65.00M	$-57.58M	$-9.66M	$-6.77M
Low Forecast	$-13.77M	$-13.77M	$-14.20M	$-13.74M	$-13.05M	$-12.45M	$-12.18M	$-9.40M	$-10.64M	$-12.01M	$-12.36M	$-14.83M	$-23.92M	$-26.23M	$-32.55M	$-19.35M	$-42.36M	$-39.82M	$-39.70M	$-18.43M	$-45.82M	$-41.52M	$-40.30M	$-18.99M	$-35.00M	$-65.00M	$-57.58M	$-14.49M	$-10.16M
Surprise %	-	-	-	-	-	-	-	-	-	0.20%	0.55%	-1.51%	0.88%	0.62%	0.61%	1.04%	1.13%	0.37%	0.31%	0.96%	0.44%	0.40%	0.06%	1.04%	0.36%	0.28%	0.36%	1.22%	1.78%

Aquestive Therapeutics's average Quarter net income forecast for Jun 23 is $-10.63M, with a range of $-12.36M to $-9.51M. AQST's average Quarter net income forecast represents a -155.04% decrease compared to the company's last Quarter net income of $19.31M (Mar 23).

Aquestive Therapeutics SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Sep 18
# Analysts	1	1	1	4	6	3	2	2	4	2	2	2	1	1	1	1	2	2	2	4	4	6	4	4	7	4	3	7	9
SG&A	-	-	-	-	-	-	-	-	-	$7.38M	$7.36M	$7.46M	$11.81M	$12.46M	$15.59M	$13.02M	$14.98M	$12.13M	$13.13M	$13.23M	$15.58M	$11.80M	$13.89M	$14.61M	$16.47M	$13.71M	$16.25M	$17.91M	$12.35M
Avg Forecast	$15.92M	$14.29M	$13.66M	$13.68M	$13.69M	$13.27M	$12.96M	$12.83M	$12.20M	$12.04M	$11.52M	$10.40M	$10.90M	$11.51M	$11.06M	$10.60M	$9.79M	$11.52M	$9.91M	$9.39M	$6.55M	$9.13M	$9.17M	$10.54M	$16.57M	$10.43M	$9.61M	$12.12M	$6.95M
High Forecast	$17.92M	$16.09M	$15.38M	$14.73M	$15.82M	$13.31M	$12.99M	$14.44M	$12.93M	$12.05M	$12.97M	$11.70M	$12.27M	$11.51M	$11.06M	$10.60M	$9.79M	$11.52M	$9.91M	$9.39M	$6.55M	$9.13M	$9.17M	$10.54M	$16.57M	$10.43M	$9.61M	$12.12M	$8.34M
Low Forecast	$14.63M	$13.13M	$12.56M	$12.85M	$12.68M	$13.24M	$12.93M	$11.79M	$11.38M	$12.04M	$10.59M	$9.56M	$10.02M	$11.51M	$11.06M	$10.60M	$9.79M	$11.52M	$9.91M	$9.39M	$6.55M	$9.13M	$9.17M	$10.54M	$16.57M	$10.43M	$9.61M	$12.12M	$5.56M
Surprise %	-	-	-	-	-	-	-	-	-	0.61%	0.64%	0.72%	1.08%	1.08%	1.41%	1.23%	1.53%	1.05%	1.32%	1.41%	2.38%	1.29%	1.52%	1.39%	0.99%	1.31%	1.69%	1.48%	1.78%

Aquestive Therapeutics's average Quarter SG&A projection for Dec 23 is $12.20M, based on 4 Wall Street analysts, with a range of $11.38M to $12.93M. The forecast indicates a 65.17% rise compared to AQST last annual SG&A of $7.38M (Sep 23).

Aquestive Therapeutics EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Sep 18
# Analysts	1	1	1	4	6	3	2	2	4	2	2	2	1	1	1	1	2	2	2	4	4	6	4	4	7	4	3	7	9
EPS	-	-	-	-	-	-	-	-	-	-	$-0.00	$0.35	$-0.37	$-0.30	$-0.44	$-0.40	$-1.19	$-0.37	$-0.33	$-0.41	$-0.60	$-0.49	$-0.07	$-0.49	$-0.48	$-0.74	$-0.82	$-0.59	$-0.64
Avg Forecast	$-0.13	$-0.13	$-0.13	$-0.13	$-0.13	$-0.12	$-0.12	$-0.09	$-0.09	$-0.11	$-0.12	$-0.14	$-0.23	$-0.29	$-0.36	$-0.42	$-0.47	$-0.44	$-0.44	$-0.42	$-0.50	$-0.46	$-0.44	$-0.47	$-0.39	$-0.71	$-0.63	$-0.52	$-0.24
High Forecast	$-0.12	$-0.12	$-0.12	$-0.11	$-0.12	$-0.11	$-0.10	$-0.08	$-0.04	$-0.10	$-0.10	$-0.13	$-0.20	$-0.29	$-0.36	$-0.42	$-0.47	$-0.44	$-0.44	$-0.42	$-0.50	$-0.46	$-0.44	$-0.47	$-0.39	$-0.71	$-0.63	$-0.52	$-0.19
Low Forecast	$-0.15	$-0.15	$-0.16	$-0.15	$-0.14	$-0.14	$-0.13	$-0.10	$-0.12	$-0.13	$-0.14	$-0.16	$-0.26	$-0.29	$-0.36	$-0.42	$-0.47	$-0.44	$-0.44	$-0.42	$-0.50	$-0.46	$-0.44	$-0.47	$-0.39	$-0.71	$-0.63	$-0.52	$-0.29
Surprise %	-	-	-	-	-	-	-	-	-	-	0.00%	-2.50%	1.64%	1.04%	1.23%	0.95%	2.55%	0.84%	0.76%	0.96%	1.19%	1.07%	0.16%	1.05%	1.25%	1.03%	1.29%	1.15%	2.67%

According to 2 Wall Street analysts, Aquestive Therapeutics's projected average Quarter EPS for Jun 23 is $-0.12, with a low estimate of $-0.14 and a high estimate of $-0.10. This represents a -133.33% decrease compared to AQST previous annual EPS of $0.35 (Mar 23).

Aquestive Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
EVOK	Evoke Pharma	$4.37	$18.00	311.90%	Buy
IRWD	Ironwood Pharmaceuticals	$4.02	$11.67	190.30%	Buy
AQST	Aquestive Therapeutics	$4.64	$10.25	120.91%	Buy
DVAX	Dynavax	$11.69	$24.50	109.58%	Buy
LNTH	Lantheus	$76.22	$146.25	91.88%	Buy
AMPH	Amphastar Pharmaceuticals	$44.16	$66.00	49.46%	Buy
ANIP	ANI Pharmaceuticals	$55.25	$79.00	42.99%	Buy
ALKS	Alkermes	$27.55	$36.38	32.05%	Hold
ORGO	Organogenesis	$3.94	$5.00	26.90%	Buy
ALIM	Alimera Sciences	$5.54	$5.75	3.79%	Hold
LFCR	Lifecore Biomedical	$6.43	$6.50	1.09%	Buy
AGRX	Agile Therapeutics	$1.51	$1.00	-33.77%	Buy
GHSI	Guardion Health Sciences	$3.22	$0.01	-99.69%	Buy

AQST Forecast FAQ

Is Aquestive Therapeutics a good buy?

Yes, according to 5 Wall Street analysts, Aquestive Therapeutics (AQST) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of AQST's total ratings.

What is AQST's price target?

Aquestive Therapeutics (AQST) average price target is $10.25 with a range of $9 to $12, implying a 120.91% from its last price of $4.64. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Aquestive Therapeutics stock go up soon?

According to Wall Street analysts' prediction for AQST stock, the company can go up by 120.91% (from the last price of $4.64 to the average price target of $10.25), up by 158.62% based on the highest stock price target, and up by 93.97% based on the lowest stock price target.

Can Aquestive Therapeutics stock reach $7?

AQST's average twelve months analyst stock price target of $10.25 supports the claim that Aquestive Therapeutics can reach $7 in the near future.

What is Aquestive Therapeutics's current price target trend?

1 Wall Street analyst forecast a $10 price target for Aquestive Therapeutics (AQST) this month, up 115.52% from its last price of $4.64. Compared to the last 3 and 12 months, the average price target increased by 115.52% and increased by 106.90%, respectively.

What are Aquestive Therapeutics's analysts' financial forecasts?

Aquestive Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $50.43M (high $54.07M, low $48.4M), average EBITDA is $-35.784M (high $-34.346M, low $-38.369M), average net income is $-41.442M (high $-37.494M, low $-47.091M), average SG&A $52.75M (high $56.56M, low $50.63M), and average EPS is $-0.455 (high $-0.412, low $-0.517). AQST's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $55.02M (high $61.29M, low $50.83M), average EBITDA is $-39.045M (high $-36.069M, low $-43.492M), average net income is $-47.909M (high $-42.415M, low $-55.488M), average SG&A $57.56M (high $64.12M, low $53.17M), and average EPS is $-0.526 (high $-0.466, low $-0.609).

Did the AQST's actual financial results beat the analysts' financial forecasts?

Based on Aquestive Therapeutics's last annual report (Dec 2023), the company's revenue was $50.58M, beating the average analysts forecast of $44.12M by 14.64%. Apple's EBITDA was $-15.102M, missing the average prediction of $-31.312M by -51.77%. The company's net income was $-7.87M, missing the average estimation of $-41.442M by -81.01%. Apple's SG&A was $31.75M, missing the average forecast of $46.16M by -31.22%. Lastly, the company's EPS was $-0.0001, missing the average prediction of $-0.455 by -99.98%. In terms of the last quarterly report (Sep 2023), Aquestive Therapeutics's revenue was $13M, beating the average analysts' forecast of $11.51M by 12.93%. The company's EBITDA was $-2.377M, missing the average prediction of $-8.17M by -70.91%. Aquestive Therapeutics's net income was $-2.035M, missing the average estimation of $-10.322M by -80.29%. The company's SG&A was $7.38M, missing the average forecast of $12.04M by -38.69%. Lastly, the company's EPS was $0, missing the average prediction of $-0.113 by -100.00%